Phreesia, Inc. (NYSE:PHR - Get Free Report) insider Yvonne Hui sold 1,878 shares of the stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total transaction of $44,790.30. Following the transaction, the insider now owns 28,449 shares of the company's stock, valued at $678,508.65. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Yvonne Hui also recently made the following trade(s):
- On Friday, January 24th, Yvonne Hui sold 127 shares of Phreesia stock. The shares were sold at an average price of $28.00, for a total transaction of $3,556.00.
- On Tuesday, January 14th, Yvonne Hui sold 362 shares of Phreesia stock. The shares were sold at an average price of $26.38, for a total transaction of $9,549.56.
- On Friday, January 10th, Yvonne Hui sold 388 shares of Phreesia stock. The shares were sold at an average price of $27.85, for a total value of $10,805.80.
Phreesia Price Performance
Phreesia stock opened at $24.09 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -16.39 and a beta of 0.82. The firm has a 50-day moving average of $26.66 and a two-hundred day moving average of $24.25. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $30.53.
Wall Street Analysts Forecast Growth
PHR has been the topic of several analyst reports. Royal Bank of Canada raised Phreesia from a "sector perform" rating to an "outperform" rating and boosted their target price for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Citigroup boosted their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. KeyCorp raised their target price on shares of Phreesia from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price target on shares of Phreesia in a report on Thursday, March 13th. Finally, Canaccord Genuity Group raised their price objective on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia has an average rating of "Buy" and a consensus price target of $31.33.
View Our Latest Analysis on Phreesia
Institutional Trading of Phreesia
A number of large investors have recently modified their holdings of the company. Rhumbline Advisers increased its holdings in Phreesia by 3.8% during the 1st quarter. Rhumbline Advisers now owns 86,844 shares of the company's stock worth $2,220,000 after purchasing an additional 3,213 shares during the period. GAMMA Investing LLC increased its stake in shares of Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after buying an additional 5,621 shares during the period. Probity Advisors Inc. bought a new stake in shares of Phreesia in the fourth quarter valued at about $304,000. PharVision Advisers LLC purchased a new stake in Phreesia in the fourth quarter worth about $302,000. Finally, Two Sigma Advisers LP bought a new position in Phreesia during the 4th quarter worth about $302,000. Hedge funds and other institutional investors own 92.10% of the company's stock.
Phreesia Company Profile
(
Get Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
